Transfusion Reduction in High-Bleeding-Risk Cardiac Surgery With Desmopressin
NCT ID: NCT07012837
Last Updated: 2025-06-10
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE3
Total Enrollment
112 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-07-31
Study Completion Date
2027-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Rationale
Bleeding after cardiac surgery is a complication that might result in increased morbidity, mortality, and cost of cardiac surgery by 1.76 (confidence interval (CI), 1.64-1.90) times and a median increase in costs by Australian $33,338 (CI, $21,943-$38,415) \[1\]. Strategies and techniques to reduce postoperative bleeding in identified high-risk patients for bleeding after cardiac surgery might improve outcomes and resource utilization.
Desmopressin (DDAVP) is used as a hemostatic agent to prevent and treat bleeding in patients with mild hemophilia patients with von Willebrand's deficiency through stimulating the release of von Willebrand factor from endothelial cells.
Previous studies showed controversial results in terms of reduced transfusion requirements in patients with low risk for bleeding with post cardiopulmonary bypass (CPB) bleeding following prophylactic infusing desmopressin over 10 to 15 minutes after induction of anesthesia or protamine administration due to its positive effects on the coagulation system responsible for such bleeding. Contradictory, prophylactic desmopressin use demonstrated fewer transfusion requirements in patients treated with antiplatelets, which raises the need to examine its efficacy in high-risk cardiac surgery patients for perioperative bleeding. These controversial results might be attributed to delayed administration of desmopressin after evolving CPB-associated thrombocytopenia, platelet dysfunction, coagulation factor consumption and dilution, hyperfibrinolysis, and hypofibrinogenemia \[2\]
Concerns were raised about the associated transient decreases in systemic vascular resistance and blood pressure after desmopressin administration following discontinuing CPB and administering protamine, which might be related to the rapid infusion rate during the critical surgery stage.
The cost of a single dose of Desmopressin 0.3 ug/kg for a patient with an average weight of 70 Kg is about 82US$ which is cheaper than the alternative hemostatic agents proved to be effective in reducing bleeding and transfusion needs after cardiac surgery (e.g., fibrinogen concrete (average of 3 g = 1,167US$) and prothrombin complex concentrate (6,255US$ considering low fixed dosfixed-doseof 1040 IU F IX).
It is yet unclear if extended infusions of desmopressin started earlier before the development of CPB-associated coagulopathy and platelets dysfunction from anesthesia induction time and continued to the end of CPB before protamine administration would offer an "efficacy," "safety, and "cost-effective" benefits over placebo in patients with high risks for bleeding after cardiac surgery terms of the need for transfusion, cumulative postoperative 48-hour chest tube outputs, need for reoperation, thrombotic complications, 30-day mortality, hemodynamic stability, and urine output during and after completing infusion, and costs of the study drug and allogenic transfusion requirement. That raises the need to examine its impact on these crucial clinical outcomes.
Objective
The primary objective of this prospective multicentre randomized clinical trial (RCT) is, compared with placebo, to examine the impact of prolonged infusion desmopressin on reducing postoperative bleeding and the need for allogenic allogeneic transfusion in high-bleeding-risk cardiac surgery patients scheduled for elective cardiac surgical procedures using CPB. Secondary objectives include comparing placebo and desmopressin in terms of safety and cost-effectiveness.
Hypothesis
It is hypothesized that extended 'desmopressin' infusion compared to 'placebo' results in less postoperative bleeding and transfusion needs (more effective) and leads to less hemodynamic compromise (safer) and cheaper (cost-effective) in high-risk cardiac surgery patients.
Bleeding after cardiac surgery is a complication that might result in increased morbidity, mortality, and cost of cardiac surgery by 1.76 (confidence interval (CI), 1.64-1.90) times and a median increase in costs by Australian $33,338 (CI, $21,943-$38,415) \[1\]. Strategies and techniques to reduce postoperative bleeding in identified high-risk patients for bleeding after cardiac surgery might improve outcomes and resource utilization.
Desmopressin (DDAVP) is used as a hemostatic agent to prevent and treat bleeding in patients with mild hemophilia patients with von Willebrand's deficiency through stimulating the release of von Willebrand factor from endothelial cells.
Previous studies showed controversial results in terms of reduced transfusion requirements in patients with low risk for bleeding with post cardiopulmonary bypass (CPB) bleeding following prophylactic infusing desmopressin over 10 to 15 minutes after induction of anesthesia or protamine administration due to its positive effects on the coagulation system responsible for such bleeding. Contradictory, prophylactic desmopressin use demonstrated fewer transfusion requirements in patients treated with antiplatelets, which raises the need to examine its efficacy in high-risk cardiac surgery patients for perioperative bleeding. These controversial results might be attributed to delayed administration of desmopressin after evolving CPB-associated thrombocytopenia, platelet dysfunction, coagulation factor consumption and dilution, hyperfibrinolysis, and hypofibrinogenemia \[2\]
Concerns were raised about the associated transient decreases in systemic vascular resistance and blood pressure after desmopressin administration following discontinuing CPB and administering protamine, which might be related to the rapid infusion rate during the critical surgery stage.
The cost of a single dose of Desmopressin 0.3 ug/kg for a patient with an average weight of 70 Kg is about 82US$ which is cheaper than the alternative hemostatic agents proved to be effective in reducing bleeding and transfusion needs after cardiac surgery (e.g., fibrinogen concrete (average of 3 g = 1,167US$) and prothrombin complex concentrate (6,255US$ considering low fixed dosfixed-doseof 1040 IU F IX).
It is yet unclear if extended infusions of desmopressin started earlier before the development of CPB-associated coagulopathy and platelets dysfunction from anesthesia induction time and continued to the end of CPB before protamine administration would offer an "efficacy," "safety, and "cost-effective" benefits over placebo in patients with high risks for bleeding after cardiac surgery terms of the need for transfusion, cumulative postoperative 48-hour chest tube outputs, need for reoperation, thrombotic complications, 30-day mortality, hemodynamic stability, and urine output during and after completing infusion, and costs of the study drug and allogenic transfusion requirement. That raises the need to examine its impact on these crucial clinical outcomes.
Objective
The primary objective of this prospective multicentre randomized clinical trial (RCT) is, compared with placebo, to examine the impact of prolonged infusion desmopressin on reducing postoperative bleeding and the need for allogenic allogeneic transfusion in high-bleeding-risk cardiac surgery patients scheduled for elective cardiac surgical procedures using CPB. Secondary objectives include comparing placebo and desmopressin in terms of safety and cost-effectiveness.
Hypothesis
It is hypothesized that extended 'desmopressin' infusion compared to 'placebo' results in less postoperative bleeding and transfusion needs (more effective) and leads to less hemodynamic compromise (safer) and cheaper (cost-effective) in high-risk cardiac surgery patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery
NCT00885924
Hemorrhage
Postoperative Blood Loss
TERMINATED
PHASE4
Desmopressin in Cardiac Surgery
NCT00337766
Hemorrhage
Blood Loss, Surgical
Postoperative Hemorrhage
COMPLETED
PHASE4
DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery
NCT03954314
Bleeding
Surgical Blood Loss
Seizures
TERMINATED
PHASE3
Dose-ranging Study of Two Doses of Tranexamic Acid During Cardiac Surgery
NCT00809393
Cardiopulmonary Bypass
Hemorrhage
COMPLETED
PHASE4
DDAVP Effect by TEG6 in Cardiac Surgery
NCT07179991
Intraoperative Bleeding
NOT_YET_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
3\. INTRODUCTION AND RATIONALE
3.1 The current role of prophylactic use of desmopressin in low-risk cardiac surgery patients.
The efficacy of "routine prophylactic administration" of desmopressin 0.3 ug/kg after anesthesia induction or protamine administration to reduce bleeding and transfusion has been revisited in a Cochrane review of 39 randomized controlled trials (RCTs) focusing on cardiac surgery \[5\] which demonstrated that compared with placebo, desmopressin used resulted in a slight decreased total volume of red blood cells (RBCs) transfused (mean difference (MD) -0.52 units, 95%CI -0.96 to -0.08 units; 14 trials, 957 participants) and total blood loss (MD -135.24 mL, 95% CI -210.80 mL to -59.68 mL; 22 trials, 1,358 participants) in adult cardiac surgery. These RCTs had low methodological quality.
Desmopressin may reduce postoperative bleeding in cardiac surgery patients who have received preoperative aspirin within 7 days of surgery, longer cardiopulmonary bypass (CPB) bypass than 140 minutes, and those with platelet dysfunction \[6\].
A recent European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology and Intensive Care (EACTAIC) guidelines on patient blood management (PBM) in adult cardiac surgery, in collaboration with the European Board of Cardiovascular Perfusion (EBCP), \[7\] concluded a task force of professionals specializing in patient blood management recommend that the prophylactic use of desmopressin is not recommended to reduce bleeding complications in cardiac surgery patients (a class III of recommendation and level A of evidence). However, it suggests considering desmopressin for bleeding patients with platelet dysfunction to reduce bleeding complications. (a class IIa of recommendation and level C of evidence).
3.2 Efficacy of Desmopressin in Reducing Postoperative Bleeding and Allogenic Blood Transfusion Needs
Although desmopressin showed a slight decrease in transfusion requirement in patients with post-CPB bleeding due to its positive effects on the coagulation system responsible for such bleeding, there is a continued debate on the "efficacy" and "safety" of prophylactic use of desmopressin for cardiac surgery \[8-9\].
A previous small study demonstrated the efficacy of desmopressin in reducing homologous blood requirement in cardiac surgical patients treated with aspirin within 5 days before surgery \[10\].
3.3. Does the timing of the Desmopressin Administration Make A Difference?
The timing of the administration of desmopressin might explain such controversial results. Infusing desmopressin following protamine administration failed to show significant differences in transfusion requirements in small studies, including few patients \[11-13\]. Similar results were reported when desmopressin was administered after chest closure \[14\]. Delaying desmopressin administration until the termination of CPB or chest closure, with its impact on the coagulation system and platelet functions, might explain these reported low or no efficacy in reducing bleeding compared with placebo. Additionally, this is contradictory to the highly recommended routine use of antifibrinolytics (class 1, Level of evidence A) and using protamine to heparin ratio of less than one (class 1, Level of evidence B) by the current EACTS/EACTAIC/EBCP Guidelines on PBM \[6\], that was not considered in these studies \[10-14\].
3.4. Can Repeating Desmopressin Administration Increase the Efficacy?
Repeating the administration of desmopressin after CPB and then 12 hours after surgery did not result in a significant difference despite the blood loss being less than that of the placebo in the former in a small, unpowered study \[15-16\].
3.5. Safety of Desmopressin Administration
Rapid infusing desmopressin over ten or 15 minutes, particularly shortly after administering protamine with its unique vasodilatation and histamine release effect, might explain the notable reduced systemic vascular resistance (SVR) and blood pressure and increased pulmonary vascular resistance (PVR) in some studies \[10-14, 16\], which was unlikely due to the associated histamine release \[17\].
Desmopressin use did not result in significant changes in urine output \[12\] or increased myocardial infarction incidence \[15\]; these studies included few patients to examine these secondary outcomes.
3.6. Can Slower Desmopressin Administration Increase Its Safety
A slower infusion of desmopressin over 30 rather than 10 minutes was only associated with less increased PVR in this small cohort \[18\]. That raises the need to examine the "safety" of a more extended infusion of desmopressin.
3.7. Can Point-of-Care Coagulation Testing Improve Efficacy of Desmopressin Administration
Point-of-care (POC) thromboelastography (TEG) guided hemostasis and transfusion reduced RBCs, plasma, and platelet transfusion, operating room (OR) length of stay (LOS), intensive care unit (ICU) LOS, and bleeding rate (P = 0.002) were reduced with compared with controls in a metanalysis include 9 RCTs, two of them on cardiac surgery patients \[19\]. However, that was not translated into associated reduced mortality rates \[19\].
Interestingly, a single-Canadian-center, retrospective, observational propensity-matched study demonstrated increased desmopressin administration after the introduction of point-of-care (POC) rotational thromboelastometry (ROTEM) testing with and associated statistically higher platelets transfusion \[20\].
3.8. Feasibility
Extended infusion of desmopressin from induction of anesthesia to the end of CPB has never been compared in terms of "efficacy," "safety," and "cost-effectiveness" in high-risk cardiac surgery patients for bleeding. Cardiac surgery in patients with a high risk for bleeding is more complex to perform, and it might take longer durations to be accomplished, increasing the overall healthcare costs, which could be unacceptable for the stakeholders. Using desmopressin infusion over a more extended period might be an "effective," "safe," and "affordable" choice.
3.6. Why this randomized clinical trial?
Infusing the same desmopressin dose of 0.3 ug/kg over a more extended duration from anesthesia induction until before administering protamine might have its potential benefits and disadvantages in patients with higher risks for bleeding. The proposed randomized clinical trial here will compare extended intraoperative infusion of 'desmopressin' with 'placebo' procedures concerning effects on cumulative blood loss, need for allogenic blood transfusion, and hemostatic drugs and their overall costs, safety, and feasibility. If 'desmopressin' is more effective and less safe and is cost-effective than the "placebo,' it should be used in this group of patients. If 'desmopressin' is comparable and less safe than the "placebo,' it should not be used in this group of patients.
3.1 The current role of prophylactic use of desmopressin in low-risk cardiac surgery patients.
The efficacy of "routine prophylactic administration" of desmopressin 0.3 ug/kg after anesthesia induction or protamine administration to reduce bleeding and transfusion has been revisited in a Cochrane review of 39 randomized controlled trials (RCTs) focusing on cardiac surgery \[5\] which demonstrated that compared with placebo, desmopressin used resulted in a slight decreased total volume of red blood cells (RBCs) transfused (mean difference (MD) -0.52 units, 95%CI -0.96 to -0.08 units; 14 trials, 957 participants) and total blood loss (MD -135.24 mL, 95% CI -210.80 mL to -59.68 mL; 22 trials, 1,358 participants) in adult cardiac surgery. These RCTs had low methodological quality.
Desmopressin may reduce postoperative bleeding in cardiac surgery patients who have received preoperative aspirin within 7 days of surgery, longer cardiopulmonary bypass (CPB) bypass than 140 minutes, and those with platelet dysfunction \[6\].
A recent European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology and Intensive Care (EACTAIC) guidelines on patient blood management (PBM) in adult cardiac surgery, in collaboration with the European Board of Cardiovascular Perfusion (EBCP), \[7\] concluded a task force of professionals specializing in patient blood management recommend that the prophylactic use of desmopressin is not recommended to reduce bleeding complications in cardiac surgery patients (a class III of recommendation and level A of evidence). However, it suggests considering desmopressin for bleeding patients with platelet dysfunction to reduce bleeding complications. (a class IIa of recommendation and level C of evidence).
3.2 Efficacy of Desmopressin in Reducing Postoperative Bleeding and Allogenic Blood Transfusion Needs
Although desmopressin showed a slight decrease in transfusion requirement in patients with post-CPB bleeding due to its positive effects on the coagulation system responsible for such bleeding, there is a continued debate on the "efficacy" and "safety" of prophylactic use of desmopressin for cardiac surgery \[8-9\].
A previous small study demonstrated the efficacy of desmopressin in reducing homologous blood requirement in cardiac surgical patients treated with aspirin within 5 days before surgery \[10\].
3.3. Does the timing of the Desmopressin Administration Make A Difference?
The timing of the administration of desmopressin might explain such controversial results. Infusing desmopressin following protamine administration failed to show significant differences in transfusion requirements in small studies, including few patients \[11-13\]. Similar results were reported when desmopressin was administered after chest closure \[14\]. Delaying desmopressin administration until the termination of CPB or chest closure, with its impact on the coagulation system and platelet functions, might explain these reported low or no efficacy in reducing bleeding compared with placebo. Additionally, this is contradictory to the highly recommended routine use of antifibrinolytics (class 1, Level of evidence A) and using protamine to heparin ratio of less than one (class 1, Level of evidence B) by the current EACTS/EACTAIC/EBCP Guidelines on PBM \[6\], that was not considered in these studies \[10-14\].
3.4. Can Repeating Desmopressin Administration Increase the Efficacy?
Repeating the administration of desmopressin after CPB and then 12 hours after surgery did not result in a significant difference despite the blood loss being less than that of the placebo in the former in a small, unpowered study \[15-16\].
3.5. Safety of Desmopressin Administration
Rapid infusing desmopressin over ten or 15 minutes, particularly shortly after administering protamine with its unique vasodilatation and histamine release effect, might explain the notable reduced systemic vascular resistance (SVR) and blood pressure and increased pulmonary vascular resistance (PVR) in some studies \[10-14, 16\], which was unlikely due to the associated histamine release \[17\].
Desmopressin use did not result in significant changes in urine output \[12\] or increased myocardial infarction incidence \[15\]; these studies included few patients to examine these secondary outcomes.
3.6. Can Slower Desmopressin Administration Increase Its Safety
A slower infusion of desmopressin over 30 rather than 10 minutes was only associated with less increased PVR in this small cohort \[18\]. That raises the need to examine the "safety" of a more extended infusion of desmopressin.
3.7. Can Point-of-Care Coagulation Testing Improve Efficacy of Desmopressin Administration
Point-of-care (POC) thromboelastography (TEG) guided hemostasis and transfusion reduced RBCs, plasma, and platelet transfusion, operating room (OR) length of stay (LOS), intensive care unit (ICU) LOS, and bleeding rate (P = 0.002) were reduced with compared with controls in a metanalysis include 9 RCTs, two of them on cardiac surgery patients \[19\]. However, that was not translated into associated reduced mortality rates \[19\].
Interestingly, a single-Canadian-center, retrospective, observational propensity-matched study demonstrated increased desmopressin administration after the introduction of point-of-care (POC) rotational thromboelastometry (ROTEM) testing with and associated statistically higher platelets transfusion \[20\].
3.8. Feasibility
Extended infusion of desmopressin from induction of anesthesia to the end of CPB has never been compared in terms of "efficacy," "safety," and "cost-effectiveness" in high-risk cardiac surgery patients for bleeding. Cardiac surgery in patients with a high risk for bleeding is more complex to perform, and it might take longer durations to be accomplished, increasing the overall healthcare costs, which could be unacceptable for the stakeholders. Using desmopressin infusion over a more extended period might be an "effective," "safe," and "affordable" choice.
3.6. Why this randomized clinical trial?
Infusing the same desmopressin dose of 0.3 ug/kg over a more extended duration from anesthesia induction until before administering protamine might have its potential benefits and disadvantages in patients with higher risks for bleeding. The proposed randomized clinical trial here will compare extended intraoperative infusion of 'desmopressin' with 'placebo' procedures concerning effects on cumulative blood loss, need for allogenic blood transfusion, and hemostatic drugs and their overall costs, safety, and feasibility. If 'desmopressin' is more effective and less safe and is cost-effective than the "placebo,' it should be used in this group of patients. If 'desmopressin' is comparable and less safe than the "placebo,' it should not be used in this group of patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Adult Patients Undergoing Cardiac Surgery
High Bleeding Risks
Planned Elective Cardiac Surgery Using CPB
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
A multicenter, parallel, two-group, prospective, multicenter, randomized, blinded comparative trial in patients with high risks of postoperative bleeding scheduled for elective cardiac surgery at the King Fahad Hospital of Imam Abdulrahman Bin Faisal University, Al Khobar and Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
Primary Study Purpose
PREVENTION
Blinding Strategy
DOUBLE
Participants
Outcome Assessors
Further minimization of bias will be achieved by involving two independent investigators. The researcher who is not responsible for providing anesthesia or performing surgery will perform the Randomization directly before the start of anesthesia. A second investigator, blinded for the randomization arm, will record the primary and secondary postoperative outcome measures.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Before induction of anesthesia, patients will receive identical and similar clear study solutions in similar size transparent 50-cc bags, including Saline will be infused over five hours at a rate of 10 ml/hr.
The local pharmacists who will not be involved in patients' care or data collection will prepare the study solution.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Before induction of anesthesia, patients will receive identical and similar clear study solutions in similar size transparent 50-cc bags, including Saline will be infused over five hours at a rate of 10 ml/hr. The local pharmacists who will not be involved in patients' care or data collection will prepare the study solution.
Desmopressin
Before induction of anesthesia, patients will receive identical and similar clear study solutions in similar size transparent 50-cc bags, including Desmopressin 0.3 ug/kg of the patient's body weight will be infused over five hours at a rate of 10 ml/hr. The local pharmacists who will not be involved in patients' care or data collection will prepare the study solution.
Group Type
ACTIVE_COMPARATOR
Desmopresin
Intervention Type
DRUG
Before induction of anesthesia, patients will receive identical and similar clear study solutions in similar size transparent 50-cc bags, including Desmopressin 0.3 ug/kg of the patient's body weight will be infused over five hours at a rate of 10 ml/hr. The local pharmacists who will not be involved in patients' care or data collection will prepare the study solution.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Before induction of anesthesia, patients will receive identical and similar clear study solutions in similar size transparent 50-cc bags, including Saline will be infused over five hours at a rate of 10 ml/hr. The local pharmacists who will not be involved in patients' care or data collection will prepare the study solution.
Intervention Type
DRUG
Desmopresin
Before induction of anesthesia, patients will receive identical and similar clear study solutions in similar size transparent 50-cc bags, including Desmopressin 0.3 ug/kg of the patient's body weight will be infused over five hours at a rate of 10 ml/hr. The local pharmacists who will not be involved in patients' care or data collection will prepare the study solution.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult 18 years or older.
* Scheduled for any type of elective cardiac surgery.
* Using CPB.
* General anesthesia is provided in an endotracheally intubated patient.
* A high risk of postoperative bleeding is defined as any of the following \[21-23\];
* Redo or repeated surgery.
* Treatment with platelet P2Y12 receptor--inhibiting drugs was discontinued for 7 days (ticlopidine, clopidogrel, and prasugrel) or 5 days (ticagrelor).
* Any known coagulation disorders.
* Hypofibrinogenemia less than 150 mg/dl.
* Platelet count \<100.000 cells/μL.
* Chronic renal failure, whether dialysis-dependent or not.
* Liver cell failure Child-Pugh class B or C or the Model for End-Stage Liver Disease (MELD) \>=29
* Infective endocarditis.
* Acute type-A aortic dissection.
* Expected surgery with CPB time longer than 150 minutes.
* Preoperative estimated Papworth Bleeding Risk Score of 8% or greater \[23\].
* Scheduled for any type of elective cardiac surgery.
* Using CPB.
* General anesthesia is provided in an endotracheally intubated patient.
* A high risk of postoperative bleeding is defined as any of the following \[21-23\];
* Redo or repeated surgery.
* Treatment with platelet P2Y12 receptor--inhibiting drugs was discontinued for 7 days (ticlopidine, clopidogrel, and prasugrel) or 5 days (ticagrelor).
* Any known coagulation disorders.
* Hypofibrinogenemia less than 150 mg/dl.
* Platelet count \<100.000 cells/μL.
* Chronic renal failure, whether dialysis-dependent or not.
* Liver cell failure Child-Pugh class B or C or the Model for End-Stage Liver Disease (MELD) \>=29
* Infective endocarditis.
* Acute type-A aortic dissection.
* Expected surgery with CPB time longer than 150 minutes.
* Preoperative estimated Papworth Bleeding Risk Score of 8% or greater \[23\].
Exclusion Criteria
* Planned for cardiac surgery without CPB;
* Planned for a combined coronary revascularization surgery and a valve or intra-cardiac surgery;
* Pregnancy;
* Consent for another interventional study during anesthesia;
* No written informed consent;
* Preoperative need for mechanical circulatory support;
* Planned for a combined coronary revascularization surgery and a valve or intra-cardiac surgery;
* Pregnancy;
* Consent for another interventional study during anesthesia;
* No written informed consent;
* Preoperative need for mechanical circulatory support;
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johns Hopkins Aramco Healthcare
OTHER
Sponsor Role
collaborator
Imam Abdulrahman Bin Faisal University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed R El Tahan
Consultant in Cardiac Anesthesia
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohamed R El Tahan, MD
Role: STUDY_CHAIR
Imam Abdulrahman Bin Faisal University
Fahad Makhdoum, MD
Role: PRINCIPAL_INVESTIGATOR
Imam Abdulrahman Bin Faisal University
Yasser F ElGhoneimy, MD
Role: STUDY_DIRECTOR
Imam Abdulrahman Bin Faisal University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Imam Abdulrahamn Bin Faisal University (Former, Dammam University)
Dammam, Eastern Province, Saudi Arabia
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Saudi Arabia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Redfern RE, Fleming K, March RL, Bobulski N, Kuehne M, Chen JT, Moront M. Thrombelastography-Directed Transfusion in Cardiac Surgery: Impact on Postoperative Outcomes. Ann Thorac Surg. 2019 May;107(5):1313-1318. doi: 10.1016/j.athoracsur.2019.01.018. Epub 2019 Feb 12.
Reference Type
BACKGROUND
Khalil MA, El Tahan MR, Khidr AM, Fallatah S, Abohamar AD, Amer MM, Makhdom F, El Ghoneimy Y, Al Bassam B, Alghamdi T, Abdulfattah D. Effects of norepinephrine infusion during cardiopulmonary bypass on perioperative changes in lactic acid level (Norcal). Perfusion. 2023 Nov;38(8):1584-1599. doi: 10.1177/02676591221122350. Epub 2022 Aug 22.
Reference Type
BACKGROUND
Vuylsteke A, Pagel C, Gerrard C, Reddy B, Nashef S, Aldam P, Utley M. The Papworth Bleeding Risk Score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleeding. Eur J Cardiothorac Surg. 2011 Jun;39(6):924-30. doi: 10.1016/j.ejcts.2010.10.003. Epub 2010 Nov 19.
Reference Type
BACKGROUND
Petricevic M, Petricevic M, Pasalic M, Golubic Cepulic B, Raos M, Vasicek V, Goerlinger K, Rotim K, Gasparovic H, Biocina B. Bleeding risk stratification in coronary artery surgery: the should-not-bleed score. J Cardiothorac Surg. 2021 Apr 21;16(1):103. doi: 10.1186/s13019-021-01473-3.
Reference Type
BACKGROUND
Baryshnikova E, Di Dedda U, Ranucci M. Are Viscoelastic Tests Clinically Useful to Identify Platelet-Dependent Bleeding in High-Risk Cardiac Surgery Patients? Anesth Analg. 2022 Dec 1;135(6):1198-1206. doi: 10.1213/ANE.0000000000006231. Epub 2022 Oct 13.
Reference Type
BACKGROUND
Orlov D, McCluskey SA, Callum J, Rao V, Moreno J, Karkouti K. Utilization and Effectiveness of Desmopressin Acetate After Cardiac Surgery Supplemented With Point-of-Care Hemostatic Testing: A Propensity-Score-Matched Analysis. J Cardiothorac Vasc Anesth. 2017 Jun;31(3):883-895. doi: 10.1053/j.jvca.2016.11.022. Epub 2016 Nov 17.
Reference Type
BACKGROUND
Dias JD, Sauaia A, Achneck HE, Hartmann J, Moore EE. Thromboelastography-guided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: A systematic review and analysis. J Thromb Haemost. 2019 Jun;17(6):984-994. doi: 10.1111/jth.14447. Epub 2019 May 13.
Reference Type
BACKGROUND
Fleming NW, Burke TA. Infusion rate and hemodynamics with desmopressin. J Cardiothorac Anesth. 1989 Dec;3(6):813-5. doi: 10.1016/s0888-6296(89)96804-x. No abstract available.
Reference Type
BACKGROUND
Jahr JS, Marquez J, Cottington E, Cook DR. Hemodynamic performance and histamine levels after desmopressin acetate administration following cardiopulmonary bypass in adult patients. J Cardiothorac Vasc Anesth. 1991 Apr;5(2):139-41. doi: 10.1016/1053-0770(91)90326-o.
Reference Type
BACKGROUND
16. Spyridakis, E., Pentilas, N., Retzios, G., Pappa, E., & Kalakonas, S. (2017). The use of desmopressin (DDAVP) as haemostatic agent in patients undergoing coronary artery bypass grafting (CABG) surgery. Journal of Cardiothoracic and Vascular Anesthesia, 31, S69.https://doi.org/10.1053/j.jvca.2017.02.153
Reference Type
BACKGROUND
Marquez J, Koehler S, Strelec SR, Benckart DH, Spero JA, Cottington EM, Torpey DJ Jr. Repeated dose administration of desmopressin acetate in uncomplicated cardiac surgery: a prospective, blinded, randomized study. J Cardiothorac Vasc Anesth. 1992 Dec;6(6):674-6. doi: 10.1016/1053-0770(92)90049-d.
Reference Type
BACKGROUND
Salmenpera M, Kuitunen A, Hynynen M, Heinonen J. Hemodynamic responses to desmopressin acetate after CABG: a double-blind trial. J Cardiothorac Vasc Anesth. 1991 Apr;5(2):146-9. doi: 10.1016/1053-0770(91)90328-q.
Reference Type
BACKGROUND
Oliver WC Jr, Santrach PJ, Danielson GK, Nuttall GA, Schroeder DR, Ereth MH. Desmopressin does not reduce bleeding and transfusion requirements in congenital heart operations. Ann Thorac Surg. 2000 Dec;70(6):1923-30. doi: 10.1016/s0003-4975(00)02176-7.
Reference Type
BACKGROUND
Reich DL, Hammerschlag BC, Rand JH, Weiss-Bloom L, Perucho H, Galla J, Thys DM. Desmopressin acetate is a mild vasodilator that does not reduce blood loss in uncomplicated cardiac surgical procedures. J Cardiothorac Vasc Anesth. 1991 Apr;5(2):142-5. doi: 10.1016/1053-0770(91)90327-p.
Reference Type
BACKGROUND
Brown MR, Swygert TH, Whitten CW, Hebeler R. Desmopressin acetate following cardiopulmonary bypass: evaluation of coagulation parameters. J Cardiothorac Anesth. 1989 Dec;3(6):726-9. doi: 10.1016/s0888-6296(89)94790-x.
Reference Type
BACKGROUND
Dilthey G, Dietrich W, Spannagl M, Richter JA. Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J Cardiothorac Vasc Anesth. 1993 Aug;7(4):425-30. doi: 10.1016/1053-0770(93)90164-g.
Reference Type
BACKGROUND
Hackmann T, Naiman SC. Con: desmopressin is not of value in the treatment of post-cardiopulmonary bypass bleeding. J Cardiothorac Vasc Anesth. 1991 Jun;5(3):290-3. doi: 10.1016/1053-0770(91)90291-z.
Reference Type
BACKGROUND
Shiffrin JS, Glass DD. Pro: desmopressin is of value in the treatment of post-cardiopulmonary bypass bleeding. J Cardiothorac Vasc Anesth. 1991 Jun;5(3):285-9. doi: 10.1016/1053-0770(91)90290-a. No abstract available.
Reference Type
BACKGROUND
7. Casselman FPA, Lance MD, Ahmed A, Ascari A, Blanco-Morillo J, Bolliger D, Eid M, Erdoes G, Haumann RG, Jeppsson A, van der Merwe HJ, Ortmann E, Petricevic M, Weltert LP, Milojevic M; EACTS/EACTAIC/EBCP Scientific Document Group. 2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP. Interdiscip Cardiovasc Thorac Surg. 2024 Oct 10:ivae170. doi: 10.1093/icvts/ivae170. Epub ahead of print. PMID: 39385501.
Reference Type
BACKGROUND
Wademan BH, Galvin SD. Desmopressin for reducing postoperative blood loss and transfusion requirements following cardiac surgery in adults. Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):360-70. doi: 10.1093/icvts/ivt491. Epub 2013 Nov 21.
Reference Type
BACKGROUND
Desborough MJ, Oakland K, Brierley C, Bennett S, Doree C, Trivella M, Hopewell S, Stanworth SJ, Estcourt LJ. Desmopressin use for minimising perioperative blood transfusion. Cochrane Database Syst Rev. 2017 Jul 10;7(7):CD001884. doi: 10.1002/14651858.CD001884.pub3.
Reference Type
BACKGROUND
PROVE Network Investigators for the Clinical Trial Network of the European Society of Anaesthesiology; Hemmes SN, Gama de Abreu M, Pelosi P, Schultz MJ. High versus low positive end-expiratory pressure during general anaesthesia for open abdominal surgery (PROVHILO trial): a multicentre randomised controlled trial. Lancet. 2014 Aug 9;384(9942):495-503. doi: 10.1016/S0140-6736(14)60416-5. Epub 2014 Jun 2.
Reference Type
BACKGROUND
Smilowitz NR, Gupta N, Ramakrishna H, Guo Y, Berger JS, Bangalore S. Perioperative Major Adverse Cardiovascular and Cerebrovascular Events Associated With Noncardiac Surgery. JAMA Cardiol. 2017 Feb 1;2(2):181-187. doi: 10.1001/jamacardio.2016.4792.
Reference Type
BACKGROUND
Thiele RH, Raphael J. A 2014 Update on Coagulation Management for Cardiopulmonary Bypass. Semin Cardiothorac Vasc Anesth. 2014 Jun;18(2):177-89. doi: 10.1177/1089253214534782.
Reference Type
BACKGROUND
Newcomb AE, Dignan R, McElduff P, Pearse EJ, Bannon P. Bleeding After Cardiac Surgery Is Associated With an Increase in the Total Cost of the Hospital Stay. Ann Thorac Surg. 2020 Apr;109(4):1069-1078. doi: 10.1016/j.athoracsur.2019.11.019. Epub 2020 Jan 2.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IABF-10-05-25
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Tranexamic Acid Dose and Confusion After Cardiac Surgery
NCT05966012
UNKNOWN
Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies
NCT06622187
ENROLLING_BY_INVITATION
PHASE4
Phase II Study to Compare MDCO-2010 vs Placebo and Tranexamic Acid in Patients Undergoing Cardiac Surgery
NCT01530399
TERMINATED
PHASE2
Tranexamic Acid Versus Dexmedetomidine for Improving Surgical Field Quality During Spine Surgeries
NCT06587620
COMPLETED
NA
Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery
NCT03376061
COMPLETED
PHASE4
Prediction of Bleeding and Transfusion Outcomes and Assessment of Perioperative Platelet Reactivity in Cardiac Surgery
NCT02277379
COMPLETED
A Randomized Comparison of Two Doses of Tranexamic Acid in Open-Heart Surgery
NCT04996368
COMPLETED
NA
Point-of-care Measurement of the Antifibrinolytic Activity of Tranexamic Acid in Cardiac Surgery
NCT06128330
RECRUITING
PHASE4
Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery
NCT02655653
COMPLETED
PHASE3
AProtinin Versus Tranexamic Acid in Cardiac Surgery Patients With High-risk for Excessive Bleeding
NCT04804345
COMPLETED
Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery
NCT07164300
RECRUITING
NA
Quantra Point-of-Care Hemostasis Monitoring
NCT06328647
RECRUITING
NA
A Preliminary Study of a New Tranexamic Acid Dosing Schedule for Cardiac Surgery
NCT00588133
COMPLETED
PHASE3
AI-driven Clinical Decision Support for Perioperative Blood Orders
NCT07223853
RECRUITING
NA
Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery
NCT00651573
COMPLETED
NA
Decreasing Postoperative Blood Loss and Seizures by Timing of Intravenous Tranexamic Acid 2 Pilot Trial
NCT06622564
NOT_YET_RECRUITING
PHASE3
Reducing Hypotensive Anesthesia Use with TXA During Orthognathic Surgery
NCT05474027
ENROLLING_BY_INVITATION
PHASE4
IV Tranexamic Acid Prior to Hysterectomy
NCT02911831
COMPLETED
EARLY_PHASE1
Do Anesthesiologists Follow Guidelines on Perioperative Use of Tranexamic Acid?
NCT05783648
COMPLETED
The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients
NCT01895101
COMPLETED
PHASE4
Comparison of Aprotinin and Tranexamic Acid in Routine Cardiac Surgery
NCT00396760
UNKNOWN
PHASE3
Prevention of Postpartum Hemorrhage With Tranexamic Acid
NCT03287336
COMPLETED
PHASE2
Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction
NCT00816127
COMPLETED
NA
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
NCT06337838
RECRUITING
PHASE3
The Effect of ACT and Tranexamic Acid on Bleeding in Cardiac Surgery
NCT06109155
RECRUITING
PHASE4